Three ADHD medications have reached American patients in the past five years, and a fourth was approved this July. For a field that spent two decades cycling the same molecules through new delivery systems, that is a genuinely unusual stretch. It has also produced a wave of questions in my office, most of which reduce to one: Should I switch?
For most patients the answer is No, and understanding why requires knowing what each new option actually is.
Simtriyo (centanafadine) is the newest, approved by the FDA in July 2026 for ages six and up. It works mainly on norepinephrine, one of the two brain chemicals the older stimulants act on, while largely leaving dopamine alone. That design has a purpose: Dopamine is where the euphoria and abuse potential of amphetamines comes from, so a medication that sidesteps it may carry less of both. The trade-off shows up in the trial data. In placebo-controlled studies, centanafadine’s benefit was roughly a third to half the size of what amphetamines produce. Its clearest advantage was sleep: Patients reported substantially less insomnia than is typical for stimulants. My reading of the evidence is that Simtriyo will earn a real place for patients whose anxiety, sleep, or substance-use history makes amphetamines a poor fit, and that patients doing well on their current stimulant have little reason to trade a larger effect for a smaller one. (I’ve published a detailed comparison of the trial numbers for readers who want them.)
Qelbree (viloxazine) arrived in 2021 for children and 2022 for adults. It’s a cousin of an older non-stimulant, Strattera, with two practical differences: It tends to start working in one to two weeks rather than four to eight, and it avoids a genetic quirk that makes Strattera unpredictable in a minority of patients. It also interacts with caffeine — a detail worth knowing for a teenager who lives on energy drinks. Like Strattera, it carries a warning about suicidal thoughts in young people, which in practice means closer check-ins during the first weeks — the same vigilance we apply to antidepressants.
Generic Vyvanse (lisdexamfetamine) may matter to more patients than either new molecule. Since the brand lost exclusivity, multiple manufacturers have entered, and for patients paying cash the price difference is substantial. The supply has been uneven, however — some strengths fill easily while others disappear for weeks — but the direction is toward a first-line stimulant becoming affordable.
The remaining recent arrivals are new packages for old molecules: Jornay PM, a methylphenidate taken at night so it’s working when a child wakes; Azstarys, a partial-prodrug stimulant; and Onyda XR, a liquid form of clonidine for children who can’t swallow pills. Each solves a specific practical problem. None changes what the medication does once it’s in the bloodstream.
Here is the comparison I find myself drawing in clinic: Choosing an ADHD medication is like choosing a route to work. The amphetamines are the highway — they’re the fastest, the most direct, and the standard against which everything is judged, although with real hazards that require attention. The non-stimulants are surface streets; slower, gentler, and sometimes exactly right — because of a history of addiction, an anxiety disorder that stimulants inflame, or side effects that never settled.
New roads are worth celebrating. Most commutes still belong on the highway.
Two more cautions as these medications get marketed: First, “new” and “better” are different claims, and for every medication above, the placebo-controlled effect sizes remain publicly available for anyone to check. Second, no head-to-head trial compares Simtriyo with the stimulants; the comparisons in circulation are statistical reconstructions, mostly funded by manufacturers, and should be read with that understanding.
If your current medication is working — attention improved, side effects tolerable, mornings functional — the arrival of new options is interesting news that requires nothing of you.
If your current medication isn’t working, this is the richest moment in 20 years to revisit the question with your prescriber, and the right conversation starts with why the current one is failing: too little benefit, too much side effect, or a schedule that doesn’t fit your life. Each answer may point to a different medication on this longer list.
